Padmashri Prof G D Yadav urges India's pharma industry to pivot from generics to value-led innovation in drug discovery and AI. NIPER-A awards 211 degrees, announces Rs 100 crore CoE grant.
Indian stock markets may open flat to lower on Wednesday. Sensex, Nifty extended losses yesterday. Key stocks like Titan, Biocon, Meesho in focus today. Read for full analysis.
Indian pharmaceutical companies, long known for generics, saw their risky innovation bets yield major commercial success in 2025 through global deals and approvals. Discover the key players and what's next for 2026.
A 26-year-old Biocon finance employee died after falling from the fifth floor of the company's Bengaluru campus. Police are investigating the incident that occurred during work hours.
A 26-year-old Biocon finance employee died after a fall at the Bengaluru office. Police suspect suicide. Biocon expresses condolences as investigation continues.
A Biocon employee was discovered deceased at the company's Electronic City campus in Bengaluru. Police have launched an investigation into the incident.
A 26-year-old Biocon employee, Anant Kumar, allegedly died by suicide at the company's Electronics City campus. Police are investigating the incident that occurred on Tuesday. Read for details.
A Biocon employee, S Anantha Kumar, died after falling from a building in Bengaluru's Electronics City. Police suspect suicide. The incident occurred on December 30, 2025.
Ajanta Pharma partners with Biocon to market weight-loss drug semaglutide in 26 markets. Deal expected to add ₹200 crore sales by FY28, enhancing its branded generics focus. Read more.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
Biocon announces merger of its biologics subsidiary with the parent company and a major Rs 4,500 crore fundraise. Explore the strategic shift and its impact on India's biotech sector.
Biocon announces full integration of its biosimilars unit, Biocon Biologics, in a deal valuing it at $5.5 billion. The move aims to create a unified powerhouse in diabetes, oncology, and immunology markets. Read more.
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
Biocon's Kiran Mazumdar Shaw faces online criticism after praising Bengaluru's infrastructure improvements. Residents dispute claims about roads and footpaths. Read more about the controversy.
Biocon stock jumps over 4% as company reviews Biologics IPO and merger options to unlock shareholder value and reduce debt. Latest market updates and analysis.
Biocon's generics business surges 24% driven by weight-loss drugs liraglutide & semaglutide. CEO Siddharth Mittal reveals strategy to capture share of the booming $95 billion GLP-1 market.
Religare Broking's Ajit Mishra reveals 3 promising stocks for short-term traders. Discover why Nestlé India, Biocon, and this infrastructure player could deliver quick returns in current market conditions.
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.
Top industry leaders hold crucial meeting with DK Shivakumar to address Bengaluru's infrastructure crisis following their public criticism of the city's deteriorating conditions.
Biocon founder Kiran Mazumdar-Shaw delivers powerful response to online trolls questioning her Kannadiga identity, reaffirming her deep roots in Karnataka with inspiring conviction.
Biocon Executive Chairperson Kiran Mazumdar-Shaw has vehemently denied fabricated reports claiming she offered to repair Bengaluru's roads, calling out misinformation circulating on social media.
Biocon founder Kiran Mazumdar-Shaw delivers powerful response to online trolls questioning her Kannadiga identity and commitment to Karnataka. Read her emotional defense of her roots.
Indian pharmaceutical leader Biocon Biologics partners with Civica to disrupt US insulin market with affordable alternatives, while also eyeing anti-obesity therapy opportunities.
Biocon chief Kiran Mazumdar-Shaw met with Karnataka Deputy CM DK Shivakumar, extending Diwali wishes while discussing Bengaluru's pressing infrastructure challenges in a cordial meeting.
Biocon chief Kiran Mazumdar-Shaw extends Diwali wishes to Karnataka Deputy CM DK Shivakumar during cordial meeting, signaling potential thaw in ongoing Bengaluru infrastructure discussions.
Biocon chief Kiran Mazumdar-Shaw defends her criticism of Bengaluru's crumbling infrastructure as Karnataka Deputy CM DK Shivakumar attacks her remarks. The war of words exposes the city's ongoing urban crisis.
Biocon Executive Chairperson Kiran Mazumdar-Shaw firmly denies Karnataka Deputy CM DK Shivakumar's claims about the company's Bengaluru expansion plans, asserting their commitment to the state is unwavering.
Karnataka Deputy CM DK Shivakumar gives a sharp retort to Biocon chief Kiran Mazumdar-Shaw's criticism of Bengaluru's infrastructure, challenging her to develop roads herself in this escalating urban development debate.